公开(公告)号：US11819554B2

公开(公告)日：2023-11-21

申请号：US15760765

申请日：2016-09-16

申请人： University of Massachusetts

发明人： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC分类号： A61K31/711 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/395 ,  A61K48/00 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/706 ,  A61K31/713 ,  C12Q1/6883 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/404 ,  A61K31/546 ,  A61K31/167 ,  A61K31/497 ,  A61K31/506 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/522 ,  A61K31/496 ,  A61P25/14 ,  A61P15/02 ,  A61K31/7105

CPC分类号： A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/711 ,  A61K31/713 ,  A61K31/7105 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

摘要： The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US20230346788A1

公开(公告)日：2023-11-02

申请号：US18324359

申请日：2023-05-26

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Susan Park PERRINE ,  Douglas FALLER

IPC分类号： A61K31/00 ,  A61K45/06 ,  A61K31/166 ,  A61K31/185 ,  A61K38/15 ,  A61K31/223 ,  A61K38/12 ,  A61K31/522 ,  A61K31/198

CPC分类号： A61K31/522 ,  A61K31/00 ,  A61K31/166 ,  A61K31/185 ,  A61K31/198 ,  A61K31/223 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

摘要： Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

公开(公告)号：US11793878B2

公开(公告)日：2023-10-24

申请号：US16980651

申请日：2019-03-18

申请人： Universiteit Gent

发明人： Maarten Vergaelen ,  Richard Hoogenboom ,  Victor Retamero de la Rosa ,  Chris Vervaet ,  Aseel Samaro ,  Valérie Vanhoorne

IPC分类号： A61K47/34 ,  A61K31/138 ,  A61K31/155 ,  A61K31/522

CPC分类号： A61K47/34 ,  A61K31/138 ,  A61K31/155 ,  A61K31/522

摘要： The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

公开(公告)号：US20230330126A1

公开(公告)日：2023-10-19

申请号：US18003984

申请日：2021-06-28

申请人： Giampietro IACHETTINI

发明人： Giampietro IACHETTINI

IPC分类号： A61K31/7076 ,  A61K31/708 ,  A61K31/522 ,  A61K9/20 ,  A61K9/48 ,  A61K9/16 ,  A61K9/46 ,  A61K9/08

CPC分类号： A61K31/7076 ,  A61K31/708 ,  A61K31/522 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2027 ,  A61K9/2009 ,  A61K9/4858 ,  A61K9/4816 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1641 ,  A61K9/0007 ,  A61K9/08

摘要： An antiviral treatment of infections from Coronavirus, in particular COVID-19, is by administration of a modified nucleoside, derived from adenosine, individually or in combination with other therapeutically active substances. In particular, 3′-deoxyadenosine, or cordycepin, is administered for the treatment of a viral syndrome from Coronavirus, in particular COVID-19, in which 3′-deoxyadenosine is administered individually or in combination with at least one inhibitor or antagonist of the adenosine receptors A1 and A3 and possibly agonist of the adenosine receptors A2a and/or A2b. The administration of 3′-deoxyadenosine is subsequent or simultaneous to the administration of the inhibitor, preferably inosine, a molecule which expresses both these functions.

公开(公告)号：US20230312520A1

公开(公告)日：2023-10-05

申请号：US18155528

申请日：2023-01-17

申请人： Arrakis Therapeutics, Inc.

发明人： Gnanasambandam KUMARAVEL ,  Jennifer C. PETTER ,  Jonathan Craig BLAIN ,  Donovan Noel CHIN ,  Chao FANG ,  Herschel MUKHERJEE ,  Neil KUBICA

IPC分类号： C07D401/14 ,  A61K47/54 ,  A61K47/68 ,  A61P25/28 ,  A61P43/00 ,  A61K9/00 ,  C07D495/04 ,  C12N15/115 ,  G01N33/50 ,  C07D401/12 ,  A61K31/522 ,  A61K39/395 ,  C12Q1/6816 ,  A61K31/65 ,  C07D217/26

CPC分类号： C07D401/14 ,  A61K47/545 ,  A61K47/6809 ,  A61P25/28 ,  A61P43/00 ,  A61K9/0019 ,  A61K9/0053 ,  C07D495/04 ,  C12N15/115 ,  G01N33/5008 ,  C07D401/12 ,  A61K31/522 ,  A61K39/395 ,  C12Q1/6816 ,  A61K31/65 ,  C07D217/26

摘要： The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

公开(公告)号：US20230304097A1

公开(公告)日：2023-09-28

申请号：US18006745

申请日：2021-08-27

申请人： Fredrik JOHANSSON SWARTLING

发明人： Fredrik JOHANSSON SWARTLING ,  Sonja HUTTER

IPC分类号： C12Q1/6886 ,  A61K48/00 ,  A61K38/45 ,  A61K31/522 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K31/522 ,  A61K38/45 ,  A61K48/0041 ,  A61K48/0066 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： A likelihood of cancer relapse is estimated for a subject by introducing ex vivo a nucleic acid molecule comprising a reporter gene under transcriptional control of a SOX9p or of a promoter operatively linked to an enhancer element comprising at least one SOX9 binding site into cancer cells obtained from a tumor sample from a subject. The cancer cells are exposed ex vivo to a cancer treatment and the amount of SOX9+ cancer cells following cancer treatment is determined based on expression of the reporter gene. The likelihood of cancer relapse following cancer treatment for the subject is estimated based on the determined amount of SOX9+ cancer cells. A combination of a viral vector comprising a suicidal gene under transcription control of a SOX9p or of a promoter operatively linked to an enhancer element comprising at least one SOX9 binding site and a prodrug can be used in treatment of a subject suffering from a cancer disease.

公开(公告)号：US11760748B2

公开(公告)日：2023-09-19

申请号：US18080570

申请日：2022-12-13

申请人： Viracta Subsidiary, Inc.

发明人： Xiaohu Deng ,  Wanping Mai ,  Robert Mcrae ,  Biljana Nadjsombati

IPC分类号： C07D401/14 ,  A61K31/506 ,  A61K31/522

CPC分类号： C07D401/14 ,  A61K31/506 ,  A61K31/522 ,  C07B2200/13

摘要： The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

公开(公告)号：US11752217B2

公开(公告)日：2023-09-12

申请号：US17726944

申请日：2022-04-22

申请人： Viking Scientific, Inc.

发明人： Paul Fisher ,  Paulina Davis

IPC分类号： A61K47/69 ,  A61K47/60 ,  A61K47/55 ,  A61K47/59 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K47/34 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K9/70 ,  A61K45/06 ,  A61K47/08

CPC分类号： A61K47/6903 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/14 ,  A61K9/7007 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K47/08 ,  A61K47/34 ,  A61K47/55 ,  A61K47/59 ,  A61K47/60

摘要： Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

公开(公告)号：US11746118B2

公开(公告)日：2023-09-05

申请号：US17459049

申请日：2021-08-27

申请人： AstraZeneca AB

发明人： Maurice Raymond Verschoyle Finlay ,  Frederick Woolf Goldberg ,  Attilla Kuan Tsuei Ting

IPC分类号： A61K31/522 ,  C07D519/00 ,  C07D473/18 ,  A61P35/00 ,  A61K31/502 ,  A61K45/06

CPC分类号： C07D519/00 ,  A61K31/502 ,  A61K31/522 ,  A61K45/06 ,  A61P35/00 ,  C07D473/18 ,  A61K31/522 ,  A61K2300/00

摘要： The specification generally relates to compounds of Formula (I):




and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

公开(公告)号：US11707465B2

公开(公告)日：2023-07-25

申请号：US17884346

申请日：2022-08-09

申请人： Ortho-Nutra, LLC

发明人： Hector L. Lopez ,  Shawn Wells ,  Tim N. Ziegenfuss

IPC分类号： A61K31/522 ,  C07D487/04 ,  A23L33/10 ,  A23L33/105 ,  A61K31/133 ,  A61K31/14 ,  A61K31/4748 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068

CPC分类号： A61K31/522 ,  A23L33/10 ,  A23L33/105 ,  A61K31/133 ,  A61K31/14 ,  A61K31/4748 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068 ,  C07D487/04 ,  A23V2002/00

摘要： A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.